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Abstract
Anti-epileptic medications encompass a wide range of drugs including anticonvulsants,
benzodiazepines, enzyme inducers or inhibitors, with a variety effects, including induction of
cytochrome P450 and other enzyme, which may lead to catabolism of vitamin D and hypocalcemia
and other effects that may significantly effect the risk for low bone mass and fractures. With the
current estimates of 50 million people worldwide with epilepsy together with the rapid increase in
utilization of these medications for other indications, bone disease associated with the use of anti-
epileptic medications is emerging as a serious health threat for millions of people. Nevertheless, it
usually goes unrecognized and untreated. In this review we discuss the pathophysiologic
mechanisms of bone disease associated with anti-epileptic use, including effect of anti-epileptic
agents on bone turnover and fracture risk, highlighting various strategies for prevention of bone
loss and associated fractures a rapidly increasing vulnerable population.
Background
Epilepsy is a major public health problem affecting nearly
50 million people worldwide [1]. Treatment with anti epi-
leptic drugs (AEDs) is generally chronic, if not life long
and may be associated with significant metabolic effects
including decreased bone mass and increased fractures
[2,3]. AEDs include a variety of drugs that may lead to
catabolism of vitamin D and hypocalcemia. In addition,
many of these medications such as the benzodiazepines,
carbamazepine (CBZ) and clonazepam (CZP), and bar-
biturates, are currently utilized in disorders other than
epilepsy such as pain and mood disorders and the prob-
lem may be a general one [4].
The adverse effects of AEDs on bone health were first
reported nearly four decades ago [5,6] and since then a
mounting body of evidence has linked a variety of bio-
chemical, metabolic and radiologic abnormalities in
bones to the use of AEDs [2,3,7]. AEDs have been identi-
fied as an independent risk factor for low bone density
and osteoporosis [8].
Low bone mass associated with AED use is largely unrec-
ognized, undetected, and untreated [2,3]. In a survey of
624 adult and pediatric neurologists designed to assess
the awareness of the effects of AED therapy on bone
health, among treating physicians, only 28% of adult and
41 % of pediatric neurologists reported screening their
patients for bone disease. In this cohort of neurologist,
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only 7% of adult and 9% of pediatric neurologists pre-
scribed prophylactic calcium and vitamin D for patients
receiving AED treatment [9]. These data underscore the
need for aggressive educational strategies to increase
screening and treatment of metabolic bone disorders
associated with AED use by the treating physicians. This
article will examine the effects of AEDs on bone health in
persons with epilepsy in light of the current understand-
ing of the mechanisms of bone disease. We will also dis-
cuss the possible preventive and therapeutic options for
bone loss in this patient population.
Bone structure and metabolism
Bone is a dynamic tissue that is remodeled continuously
throughout life (Figure 1). Specialized cells called osteob-
lasts initiate bone formation, osteocytes monitor bone
mechanical stresses, and osteoclasts resorb bone. Bone
density is determined by the dynamic balance between
bone formation and bone resorption. Formation starts
with the deposition of an organic matrix by osteoblasts
followed by the process of mineralization [10]. The
organic matrix is comprised predominantly of type I col-
lagen (90–95%) with contributions from various other
proteins including osteocalcin, osteonectin, osteopontin
and thrombospondin [10]. The mineral phase of bone,
hydroxyapatite, is composed of calcium and phosphorus.
The concentration of these ions in plasma and extracellu-
lar fluid determines the rate at which hydroxyapatite is
formed and deposited. There is a critical limit for the con-
centrations of calcium and phosphorus ions below which
the mineralization of organic matrix does not occur [10].
Development of osteoblasts and osteoclasts from bone marrow progenitors Figure 1
Development of osteoblasts and osteoclasts from bone marrow progenitors. Factors affecting the development and 
function of these cells, bone resorption by osteoclast and new bone formation by osteoblasts. Abbreviations: GH: growth 
hormone, IGF: insulin like growth factors, PTH: parathyroid hormone
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The functions of osteoblasts are controlled by a variety of
growth factors including insulin like growth factors I and
II, parathyroid hormone (PTH), and vitamin D3 [1, 25
(OH)  2 D3] [10]. Increased osteoblast activity results in
elevated serum concentration of bone-specific alkaline
phosphatase and osteocalcin which serve as serum mark-
ers of bone formation [10]. Histologically, active osteob-
lasts are distinguished by a specific skeletal form of
alkaline phosphatase, and receptors for PTH and vitamin
D3 [10].
After the deposition and mineralization of the bony
matrix, the osteoblasts transform into osteocytes and
function as mechanosensors. They sense mechanical
stresses and transmit signals to initiate bone remodeling
along the lines of force produced by these stresses [10].
Remodeling requires recruitment of osteoclasts, multinu-
cleate cells responsible for bone resorption. Osteoclasts
are indirectly regulated by osteoblasts although their dif-
ferentiation and function is also modulated by a number
of growth factors and cytokines including tumor necrosis
factor, interferon gamma, and interleukins. Osteoclasts
have a variety of lysosomal enzymes including protein-
ases, a specialized proton pump ATPase, and carbonic
anhydrase type II. These enzymes create and maintain an
acid environment to solubilize the mineral phase and
resorb the bone matrix [10]. This is followed by well coor-
dinated osteoblastic activity to lay down new bone in the
areas of bone resorption and restore the bone strength
along the lines of stress (Figure 1).
A number of biochemical markers can be measured that
reflect the overall rate of bone remodeling. These can be
divided into markers of bone formation derived from
osteoblasts and markers of bone resorption representing
degraded products of osteoclastic activity [10]. Alkaline
phosphatase is a marker for osteoblasts and its cellular
levels correlate with rates of bone formation. Other circu-
lating markers of bone formation include osteocalcin and
type I procollagen C-terminal peptide (PICP) [10]. Uri-
nary markers of bone resorption include hydroxyproline,
hydroxylysine and bone specific hydroxypyridinium col-
lagen cross links. Bone turn over and hence bone markers
are physiologically elevated during growth periods and
bone repairs [10]. In healthy individuals, bone turnover is
a function of age and levels of bone markers reflect the
state of bone remodeling at any given point of time. Their
primary use is for monitoring excessive bone remodeling
and the response to treatment of osteoporosis [10].
Bone remodeling is regulated by several circulating hor-
mones and growth factors including estrogens, andro-
gens, vitamin D, PTH, Tumor necrosis factor (TNF) and
insulin like growth factors (IGF) I & II. Nutrition, calcium
intake and physical activity also influence bone remode-
ling. Increased sex hormone production at puberty is cru-
cial for achievement of peak bone mass. Bone loss may be
exaggerated in women after menopause or pathologically,
in either sex, with any form of hypogonadism [10]. Many
other factors, including medications such as steroid &
AEDs, have been implicated for low bone density and
increased risk of fractures.
Both PTH and vitamin D play important roles in develop-
ment and maintenance of bone mass by maintaining cal-
cium and phosphate homeostasis and modulating
osteoblastic and osteoclastic functions. PTH increases
osteoclastic bone resorption by activating the receptor
activator of NFkappaB ligand (RANKL) on osteoblasts.
Vitamin D3 promotes differentiation along the osteoclas-
tic pathway through receptors located on osteoclast pre-
cursors [10]. Elevated PTH levels, either as primary
abnormality or as a compensatory response to hypocal-
cemia, can activate osteoclastic bone resorption to main-
tain normocalcemia. Deficiency of vitamin D may
adversely affect mineralization of bone matrix and com-
promise bone strength and is an established independent
risk factor for low bone mass and fracture [11,12]. As die-
tary sources of vitamin D are limited, most people depend
on adequate sun exposure to ensure cutaneous synthesis
of vitamin D from cholesterol precursors. This is particu-
larly important in geographic areas with limited sunlight
such as the northern hemisphere [13]. Severe vitamin D
deficiency results in defective mineralization of the skele-
ton predisposing to rickets in children and osteomalacia
in adults [11].
Bone mineral density is a surrogate marker for measuring
bone mass and bone strength. In a healthy population,
skeletal mass and BMD increases throughout childhood
and adolescence with achievement of peak bone mass in
early adulthood [10]. After the age of 30–45 years, bone
resorption exceeds bone formation and BMD begins to
decrease. This imbalance may begin at different ages and
may be variable at different skeletal sites [10].
The gold standard for BMD measurement is Dual-Energy
X-ray Absorptiometry (DEXA) with an accuracy of up to
99% at any given site [14]. The measurement is usually
made at the lumbar spine, femoral neck, and forearm pro-
viding representative samples of trabecular, mixed, and
cortical bone respectively [14]. Results are expressed as a T
score, the number of standard deviations (SD) from the
mean peak BMD for a given population. Osteoporosis is
defined clinically as the presence both of a fragility frac-
ture and of low bone mass. Operationally, osteoporosis is
defined as a bone density more than 2.5 SD below the
mean peak BMD (T score < -2.5) and osteopenia is
defined as BMD between 1 and 2.5 SD below the mean
peak value (T score <-1 & > -2.5) while BMD with T scoreNutrition & Metabolism 2006, 3:36 http://www.nutritionandmetabolism.com/content/3/1/36
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> -1 is reported normal. The fracture risk correlates well
with the bone mass & BMD and increases 2 fold with each
SD decrease in BMD [14] (Figure 2).
Effects of epilepsy on bone
Epilepsy increases the risk for fracture by a variety of
mechanisms in addition to those attributed to the use of
AEDs. The fracture rate in patients with epilepsy is 2–6
times higher than the rate observed in the general popula-
tion [15-17]. This increase in fracture risk in subjects with
epilepsy is comparable to that seen with chronic steroid
use [18] and represents an increased risk of falls as well as
increased bone fragility.
Falls are more common in patients with epilepsy as com-
pared to matched controls [16-18]. Interestingly, seizure
activity does not explain the majority of falls in epileptic
patients; approximately two thirds of falls occur in the
absence of a seizure [19] with only one third directly
attributed to seizure activity [20,21]. Epilepsy may be part
of a syndrome associated with a variety of neurological
deficits leading to weakness, loss of coordination, altered
sensory modalities and impaired cognition. Furthermore,
most of the AEDs, benzodiazepines, anticonvulsants such
as valproic acid and barbiturates, have CNS effects, and
their use is associated with neurologic side effects includ-
ing somnolence, ataxia and tremor which may also con-
tribute to gait disturbances with consequent increased risk
of falls and fractures [22]. In a prospective cohort study of
more than 8,000 community-dwelling women older than
65 years participating in the fourth examination of the
Study of Osteoporotic Fractures, AED users were 75%
more likely to have a fall compared to those who did not
use AEDs [23]. In this study, other CNS-active medica-
Decrease in peak bone mass with age and increase in fracture risk with increasing age Figure 2
Decrease in peak bone mass with age and increase in fracture risk with increasing age.
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tions such as benzodiazepines and antidepressants were
associated with increased risk of falls. These findings
underscore the importance of the CNS-related effects of
AEDs in increasing fracture rates.
Quality of life studies in patients with epilepsy suggest
that activity is frequently limited by the patients and their
families out of concern for provoking a seizure and its
consequences [24]. Immobility, inactivity, and fewer
weight bearing activities are strong risk factors for oste-
oporosis [10]. Additionally, many persons with epilepsy
are institutionalized which may decrease their activity sta-
tus. Institutionalized patients have high rates of neuro-
logic comorbidities, further decreasing mobility. The
presence of focal weakness and immobility may induce
osteopenia and bone loss in the affected limb or limbs.
This may even occur in the axial skeleton if immobility is
prolonged or if subject is bed ridden [10]. Studies in insti-
tutionalized patients with epilepsy have demonstrated
high risk of fracture in this population [25].
A number of earlier studies reported rickets and osteoma-
lacia in institutionalized subjects with epilepsy [6,26,27].
Recent studies did not observe significant presence of rick-
ets or osteomalacia in patients with epilepsy who are
ambulatory [28-30]. However, milder vitamin D defi-
ciency is fairly common in this population and has been
reported in more than half of medical inpatients [13].
More subtle deficiency of vitamin D may be associated
with secondary hyperparathyroidism and increased bone
turn over and may predispose to rapid bone loss and oste-
oporosis. Patients with epilepsy who are housebound or
institutionalized patients with epilepsy are at high risk of
vitamin D deficiency due to inadequate sunlight expo-
sure. In addition, sun exposure is often restricted with
AEDs such as carbamazepine, to reduce the occurrence of
sun light induced rash.
Effects of AEDs on bone metabolism
Effect on fracture rates
Accumulating evidence has linked AED use with increased
fracture rates in both the community-dwelling [31] and
hospitalized populations [25]. In a population based
study, the use of AEDs was associated with significantly
high risk of fracture (odds ratio 1.14–1.79) and a dose
response relationship was reported with carbamazepine
(CBZ), phenobarbital (PB), oxcarbazepine (OXC), clon-
azepam (CZP) and valproate (VPA). Fracture risk was
higher for hepatic enzyme inducing AEDs such as pheny-
toin (DPH), CBZ and PB, than for non-inducing AEDs
[21]. In another large population based study, continued
AED use was associated with higher risk of bone loss at
hip sufficient to increase the risk of hip fracture by 29%
over 5 years [22].
Factors affecting bone remodeling
Since the first reports of adverse bone effects of AEDs
more than 3 decades ago [5,6,26], a number of biochem-
ical abnormalities of bone metabolism have been
reported with AED use including hypocalcemia, hypo-
phosphatemia, low vitamin D levels and increase in PTH
[2,3,7,32]. This constellation of effects has been demon-
strated in both children and adults and is commonly seen
with AEDs that induce cytochrome P450 enzymes, partic-
ularly DPH, CBZ and PB [33-38]. These enzyme inducing
AEDs may increase catabolism of vitamin D resulting in
hypophosphatemia and hypocalcemia. Moreover, AEDs
may inhibit cellular response to PTH. Both mechanisms
have been proposed and may contribute to increases bone
remodeling [3,39]. DPH has additional effects that can
lead to hypocalcemia. DPH decreases intestinal cation
transport and calcium absorption as well as vitamin D
mediated calcium absorption[3,7]. However, the data are
not consistent and many studies failed to observe any sig-
nificant decrease in serum calcium and phosphate levels
with use of enzyme-inducing AEDs [30,40,41].
VPA, a hepatic enzyme inhibitor, is also associated with
decreased BMD and is thought to act by stimulating oste-
oclast activity [28]. Studies of VPA and calcium levels are
contradictory [42,43].
Decreased urinary excretion of calcium with use of AEDs
(CBZ, DPH, VPA) has been reported in both children [34]
and adults [33]. Surprisingly, in the latter study [33],
decrease in urinary calcium excretion with CBZ and DPH
was limited to female participants only. The mechanism
underlying this hypocalciuric effect of AEDs is unknown
and needs further exploration. Although the evidence for
newer AEDs is still limited, lamotrigine and topiramate
have not been shown to cause significant effects on serum
calcium and phosphate[2,3,7].
Low levels of biologically active vitamin D in patients on
AEDs have been demonstrated in a number of studies
[33,37,44-46], particularly with use of hepatic enzyme
inducing medications like PB, PD, DPH and CBZ. This
effect has been attributed to metabolism of vitamin D to
polar inactive metabolites by the hepatic microsomes [3].
However, the data are not consistent and some studies
have not shown significant reductions in vitamin D levels
with use of AEDs[30,47].
Elevation of serum parathyroid hormone levels has been
reported with use of AEDs in subjects with epilepsy
[33,36]. This rise in PTH levels likely represents a second-
ary response to low vitamin D levels. However, high PTH
has also been demonstrated independent of vitamin D
deficiency [36]. High PTH levels may increase bone turn-
over and predispose to low bone mass [36]. High boneNutrition & Metabolism 2006, 3:36 http://www.nutritionandmetabolism.com/content/3/1/36
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turnover has also been demonstrated with AED use
despite normal levels of PTH [42,44]. Another proposed
mechanism for the bone effects of AEDs is the inhibition
of the cellular response to PTH [3]. Animal studies have
shown that use of PB and DPH was associated with
impaired PTH response [3] although this effect has not
been confirmed in human studies.
AEDs and markers of bone turnover
Increase in the markers of bone remodeling with use of
AEDs has been demonstrated in a number of small studies
[42,46-51]. Increases in serum levels of total and bone
specific alkaline phosphatase, osteocalcin and PICP have
been reported, often associated with increase in bone
resorption markers such as N-telopeptide of type I colla-
gen (NTX) and carboxy-terminal telopeptide of type I col-
lagen (ICTP) [42,46-51]. These markers may be increased
even in the presence of normal vitamin D and PTH levels
[47]. Increased bone turnover has been observed in both
children and adults and has been associated with use of
enzyme inducing AEDs, particularly DPH, CBZ and the
enzyme inhibitor, VPA. In many cases, the increased bone
turnover was associated with decrease in BMD and may be
an important contributing mechanism [42,44,51]. Histo-
logically, biopsies of patients treated both with enzyme-
inducing and enzyme-inhibiting AEDs suggest the bone
disease is due mainly to an increased frequency of remod-
eling activation and bone turnover, rather than a mineral-
ization defect [52]. Data from the newer, non-enzyme
inducing AEDs are still limited.
Gender may influence the response of bone to AEDs as
some studies have shown different responses in men and
women. One study reported decreases in urinary deoxypy-
ridinoline levels in male epileptic patients receiving mul-
tiple AEDs but not in women or with use of single AED
[33].
Effects of AEDs on bone density
Many epidemiological studies now link AED use to
decreased bone mass in both sexes [22,29,53]. In a large
study of postmenopausal Caucasian women 65 years and
older [22], continued use of AEDs was associated with
almost 2 fold increase in rates of bone loss at hip and cal-
caneous, sufficient to increase the risk of hip fracture by
29% over 5 years. DPH was the only AED where a specific
significance could be assigned. The other AEDs were used
in insufficient numbers of patients. In one study of 81
men in the age group of 25–54 years [53], significant
declines in femoral neck BMD (annualized loss 1.8%)
were observed in those in the youngest age group (25–44
years), suggesting that effect of AED may be more pro-
nounced in the younger rather than older age group. This
is a particularly concerning as AEDs are typically used for
long periods of time and may be used for life. No causal
association was found with a specific type of AED. Age
and duration of AED use correlated significantly with low
femoral BMD [53]. Similar associations were also
reported in children where significant decreases in height
to less than 10th percentile in children were seen with AED
use [29].
Gender differences have been noted in the effects of AEDs
on bone density. In several of the studies showing loss of
bone mass with AED use, the effects are more marked in
women [33,54] and in patients with restricted activity
[29,40]. Duration of AED use also predicted bone loss as
did polypharmacy[44,51,55,56], although small sample
size and differing methodologies make these studies diffi-
cult to compare.
Hepatic enzyme inducing AEDs are implicated in bone
loss as is the hepatic enzyme inhibitor, VPA. Of the newer
AEDs, with fewer hepatic effects, LTG has been used in
some studies without significant effect on bone metabo-
Table 1: Proposed mechanisms contributing to AED induced bone disease.
• Vitamin D Inactivation
• Hepatic enzyme induction
• PXR activation
• Altered calcium metabolism (DPH)
• ↓ Intestinal absorption
• ↓ vitamin D mediated absorption
• ↓ intestinal cation transport
• ↑ PTH
• Vitamin D insufficiency
• ↓ cellular response to PTH
• Vitamin K deficiency
• ↓ Calcitonin
• Osteoblast Inhibition
• Altered sex-steroid & SHBG metabolism
• Possible modulation of Aromatase activity
Abbreviations: PXR: Pregnane X receptor, DPH: phentyoin, PTH: parathyroid hormone, SHBG: sex hormone binding globulinNutrition & Metabolism 2006, 3:36 http://www.nutritionandmetabolism.com/content/3/1/36
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lism [43]. The carbonic anhydrase inhibitors, topiramate
and zonisamide, were linked to increased risk of fractures
in a few small studies [7].
Mechanism of bone loss with AED use
The exact mechanisms for adverse bone effects of AEDs
have not been determined although many factors are
known to influence and modify these effects (Table 1).
Enzyme-inducing AEDs such as DPH and CBZ have been
shown to decrease vitamin D levels. Deficiency of vitamin
D can lead to bone loss by causing hypocalcemia, hypo-
phosphatemia and secondary hyperparathyroidism [11].
Low levels of vitamin D with AED use have been reported
in many studies but significant correlation with BMD has
generally not been observed [33,44,45]. Vitamin D has
significant effects other than calcium homeostasis and
secondary hyperparathyroidism. It is an important modu-
lator of osteoblastic function and also facilitates differen-
tiation along the osteoclastic lines [10]. Vitamin D
deficiency associated with use of AEDs is likely mediated
through the orphan nuclear receptor, pregnane X receptor
(PXR) [57] (Figure 3). The PXR shares 60% homology in
their DNA binding domains with the vitamin D receptor
(VDRs) and is expressed in intestine, kidney and liver.
PXR has been shown to mediate induction of CYP 2 and
CYP 3, the cytochrome P450 enzymes involved in the
drug metabolism. Furthermore, PXR can be activated by a
variety of pharmaceutical agents including phenytoin,
phenobarbital, carbamazepine and rifampicin [57].
Representation of pregnane X receptor (PXR) mediated vitamin D catabolism Figure 3
Representation of pregnane X receptor (PXR) mediated vitamin D catabolism. PXR is activated by various antiep-
ileptic medications and other pharmaceutical agents and induces CYP 24, the enzyme which metabolises active vitamin D3 to 
inactive form. Abbreviations: PXR: Pregnane X receptor, DPH: phentyoin, CBZ: carbamazepine, PB: phenobarbital, VDR: 
vitamin D receptor, PTH: parathyroid hormone, CYP 24: 24-hydroxylase.
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Emerging evidence shows that these PXR activators can
increase the expression of the CYP24, a VDR target gene in
cultured cells and in vivo in mice. CYP 24 is an enzyme
that directs the side chain oxidation and cleavage of 25
(OH)2 D3 and 1β, 25 (OH)2 D3 to carboxylic acid end
products (calcitroic acid), resulting in lower cellular con-
centration of active vitamin D. This induces a state of vita-
min D deficiency and results in hypocalcemia, secondary
hyperparathyroidism and increased bone turnover predis-
posing to low bone density and bone loss [57,58]. This,
however, does not explain the deficiency of vitamin D
with VPA reported in some studies as VPA is an inhibitor
of cytochrome P450 enzymes and is not among the
known activators of PXR.
With the demonstration of significant homology between
VDR and PXR, it is conceivable that the effects of PXR acti-
vation by pharmaceutical agents like AEDs may be not be
limited to inactivation of vitamin D and may potentially
interfere with many other VDR controlled physiological
processes including cellular and bone effects [57,58].
These may affect growth and maturation of osteoclasts
and function of osteoblasts leading to adverse effects on
bone health [57].
Decreased vitamin D3 levels may affect osteoblast activity
through the aromatase pathway [59]. Aromatase is an
enzyme present in many extragonadal tissues including
bones, liver, skin and functions to convert the circulating
androgens to estrogens [59]. Evidence from a study in
postmenopausal women suggests positive correlation
between BMD and serum dehydroepiandrosterone sulfate
(DHEAS) and estrone levels but not with estradiol levels
[59,60]. This suggests that conversion of adrenal andro-
gens to estrogen in peripheral tissues plays an important
role in maintaining BMD in postmenopausal women.
Vitamin D3 is an important regulator of aromatase activity
and physiological concentrations of vitamin D3 are neces-
sary for maintenance of aromatase activity in osteoblasts
[59]. In addition, AEDs can decrease the availability of
androgen substrates for aromatase pathway by increasing
the catabolism of sex steroids and increasing SHBG levels,
resulting in reduced free testosterone and DHEA levels
[61-64].
Many studies have shown AEDs increase bone turnover
and this may contribute to bone loss[3,7]. Factors associ-
ated with AED use, such as vitamin D deficiency, hyper-
parathyroidism and calcitonin deficiency [50], have been
implicated in causing increased bone turnover. DPH and
CBZ have been demonstrated to inhibit the proliferation
of human osteoblast-like cell at concentrations equal to
therapeutic doses[44]. VPA, a hepatic enzyme inhibitor,
has been reported to act by stimulating osteoclast activity
[28] and may cause imbalance between bone formation
and resorption, contributing to bone loss. DPH has also
been shown to inhibit osteocalcin secretion from osteob-
lasts [65] and may have more than one mechanism for
bone effects.
DPH can cause vitamin K deficiency by increasing its
metabolism and is frequently associated with hemor-
rhagic disease of the newborn when used in pregnant
woman. Vitamin K is an essential cofactor for post trans-
lational carboxylation of various Gla bone proteins
including osteocalcin [7]. DPH induced vitamin K defi-
ciency can potentially cause bone loss by preventing the
post translational modification of the vitamin K depend-
ent matrix proteins. Supplementation with vitamin K has
been shown to reduce bone loss in DPH treated rats [3]
though there are no data from human studies.
Hepatic enzyme inducing AEDs can alter the synthesis
and metabolism of sex steroids, serum levels of sex hor-
mone binding globulin (SHBG) as well as central feed-
back mechanisms [61,62,66]. CBZ, DPH and VPA have
been reported to directly inhibit testosterone biosynthesis
by Leydig cells of testes in animal studies[63]. Increased
clearance of androgens, including testosterone has been
reported with DPH, CBZ and PB [62]. Furthermore,
chronic CBZ and DPH treatment can increase SHBG levels
with resultant decrease in free testosterone, estradiol and
androsteindione levels. These changes may predispose to
accelerated bone loss in subjects taking AEDs by reducing
the androgen substrates for aromatase activity [62,64].
Management of AED-induced bone loss
In absence of long-term randomized controlled trials eval-
uating different therapeutic options, most of the recom-
mendations for management of AED-induced bone loss
must be considered empirical though consistent with cur-
rent evidence.
Good bone health practices
Discussion of the risks associated with AEDs and good
bone health practices should be part of the evaluation of
a seizure patient. Good bone health practices include reg-
ular weight-bearing exercise, adequate sunlight exposure,
adequate intake of calcium and avoidance of risk factors
for osteoporosis such as smoking and alcohol use. High
risk patients should be identified before start of AED treat-
ment and evaluated as recommended in later section.
High risk patients include institutionalized and non-
ambulatory subjects, those with poor dietary habits and
limited sun exposure such as at higher latitudes, those on
multiple AEDs and with increased duration of AED use.
Those with multiple traditional osteoporosis risk factors
as well as low calcium and vitamin D levels should also be
considered at high risk and treated aggressively.Nutrition & Metabolism 2006, 3:36 http://www.nutritionandmetabolism.com/content/3/1/36
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Calcium supplementation
Calcium supplementation with doses of 1–1.5 gm/day
should be offered to all persons using AEDs, particularly
in presence of multiple risk factors or documented low
BMD [32,67].
Vitamin D
Prophylaxis with vitamin D has been recommended for
all subjects using AEDs [3,7,52,68,69]. Due to increased
catabolism of vitamin D, higher than normally recom-
mended doses (up to 4000 IU per day) of vitamin D may
be required for optimal effect, particularly for those with
low vitamin D levels, high risk of bone disease and/or
with documented low BMD [11,52,68]. Since the current
RDI of 400 IU of vitamin D is not considered sufficient
even in healthy adults [11], a dose of 800–1000 IU/day of
vitamin D is reasonable as a preventive therapy in subjects
using AEDs. For those with documented vitamin D defi-
ciency, treatment with 50,000 IU/week for 8 weeks has
been recommended and can be repeated if vit D levels
remain low after initial treatment. This may be followed
by supplementation with vitamin D 50,000 IU once a
month to maintain the levels above the threshold of
insufficiency [11].
Surveillance
There is no clear consensus on recommendations for sur-
veillance of bone disease associated with AEDs. Based on
our experience, we recommend the following:
a) Baseline and then 6–12 months monitoring of serum
calcium, phosphate, alkaline phosphatase, PTH and vita-
min D levels.
b) Baseline screening with DEXA scan before initiating
AED treatment in all high risk adults such as post meno-
pausal women or subjects with multiple risk factors and
then periodically at 1–2 year intervals.
c) Subjects with intermediate risk such as those with epi-
lepsy on AEDs and one other risk factor may be screened
with DEXA scan after 2 years of AED treatment.
d) In the subjects with no other osteoporosis risk factors,
screening with DEXA scan may be appropriate after 5
years on AEDs [32].
e) Subjects with abnormal levels of above parameters and
those with multiple risk factors for osteoporosis or low
BMD on DEXA scan should preferably be evaluated and
managed by endocrinologists.
f) In children, the value of BMD measurement before the
development of peak bone mass without establishment of
adequate reference ranges is questionable and needs to be
evaluated further. However, as various studies have
detected low bone mass with DEXA in pediatric age group
as well, it should be probably offered to those at high risk
as mentioned previously.
Treatment
Recommendations for treatment of AED associated low
bone mass depend on the severity of the bone disease.
a) Subjects with normal bone mass (T score > -1) should
be encouraged to follow good bone health practices in
addition to calcium and vitamin D supplementation.
b) For subjects with osteopenia (T score < -1 and > -2.5),
in addition risk modification as above, antiresorptive
treatment may be indicated for those with significant dis-
ease (T score < -1.5) and multiple risk factors for low bone
mass. These subjects may benefit from a specialist evalua-
tion.
c) For adults with osteoporosis (T score < -2.5) and or fra-
gility fractures, treatment with antiresorptive medications
is indicated in addition to calcium & vitamin D supple-
mentation. These subjects should preferably be evaluated
by endocrinologist and secondary causes for low bone
mass ruled out as appropriate.
d) In postmenopausal women, hormone replacement
therapy may retard the bone loss but the possibility of
increase in seizure activity needs to be seriously consid-
ered in addition to risk of thromboembolism and breast
cancer.
e) Oral bisphosphonates (alendronate, risedronate and
ibandronate) may be considered for adults with signifi-
cant osteopenia or osteoporosis although there are no
established data for its use in AED induced bone loss spe-
cifically. Vitamin D insufficiency should be treated prior
to starting bisphosphonates. Newer bisphosphonates are
now available which can be used once a month (Ibandro-
nate). For subjects who cannot tolerate oral bisphospho-
nates, treatment with parenteral agents such as
ibandronate may be considered.
f) BMD with DEXA scan should be monitored at regular
intervals of 12–18 months to monitor the response to
therapy. Bone resorption markers such as N-telopeptide
(NTX) may also be used to monitor the response to ther-
apy as an adjunct to BMD testing.
g) Role of bisphosphonates in children or adolescents
with low bone mass prior to achievement of peak bone
mass has not been evaluated. Such therapy should be
offered only after consideration of potential risks and ben-
efits and should be appropriately individualized.Nutrition & Metabolism 2006, 3:36 http://www.nutritionandmetabolism.com/content/3/1/36
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Conclusion
Although epilepsy represents a group of heterogeneous
disorders and the AEDs have multiple pharmacologic
effects, accumulating evidence shows that exposure to
AEDs confers an increased risk of osteoporosis and frac-
ture. The current evidence also suggests that young adults
may be at particularly increased risk of bone loss. Low cal-
cium intake and vitamin D deficiency may aggravate these
bone effects and are potentially treatable factors. Inactivity
is another important factor associated with bone loss and
needs to be considered in the management of bone dis-
ease associated with AEDs. Despite the evidence suggest-
ing adverse effects of AEDs on bone, there appears to be a
general lack of awareness among physicians about these
effects. Although there is a lack of any definitive screening
or treatment guidelines, those screening, monitoring and
treatments that are easily available are not effectively uti-
lized. Since these bone effects of AEDs, particularly osteo-
penia and osteoporosis, tend to be serious and encompass
significant health care and financial costs, more attention
needs to given and guidelines for their screening and treat-
ment need to established.
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